NEW HORIZONS

Immunological Aspects of Antiviral Therapy of Chronic Hepatitis B Virus and Hepatitis C Virus Infections

Barbara Rehermann¹ and Antonio Bertoletti²,³

Hepatitis B virus (HBV) and hepatitis C virus (HCV) cause a large proportion of acute and chronic liver disease worldwide. Over the past decades many immunological studies defined host immune responses that mediate spontaneous clearance of acute HBV and HCV infection. However, host immune responses are also relevant in the context of treatment-induced clearance of chronic HBV and HCV infection. First, the pretreatment level of interferon-stimulated genes as well as genetic determinants of innate immune responses, such as single nucleotide polymorphisms near the IFNL3 gene, are strong predictors of the response to interferon-alpha (IFN-α)-based therapy. Second, IFN-α, which has been a mainstay of HBV and HCV therapy over decades, and ribavirin, which has also been included in interferon-free direct antiviral therapy for HCV, modulate host immune responses. Third, both IFN-α-based and IFN-α-free treatment regimens of HBV and HCV infection alter the short-term and long-term adaptive immune response against these viruses. Finally, treatment studies have not just improved the clinical outcomes, but also provided opportunities to study virus-host interaction. This review summarizes our current knowledge on how a patient’s immune response affects the treatment outcome of HBV and HCV infection and how innate and adaptive immune responses themselves are altered by the different treatment regimens. (Hepatology 2015;61:712-721)

Spontaneous hepatitis B virus (HBV) and hepatitis C virus (HCV) clearance occurs most frequently in the acute phase of infection and is mediated by vigorous adaptive immune responses. In contrast, spontaneous viral clearance rarely occurs in the chronic phase of HBV infection and almost never in the chronic phase of HCV infection when virus-specific T-cell responses are exhausted. While host immune responses that result in spontaneous HBV and HCV clearance have been extensively characterized, it has recently become clear that they also play a role in the context of antiviral therapy in chronic infection (Table 1).

Immunological Aspects of HBV Antiviral Therapy

When assessing the prospects of successful antiviral therapy of chronic HBV infection one has to consider that even spontaneously recovered patients do not completely clear HBV and may reactivate the infection upon immunosuppression, e.g., during cancer chemotherapy or organ transplantation.¹ Spontaneous recovery with seroconversion to hepatitis B virus surface antigen (HBsAg)-negative/anti-HBs-positive is observed in >95% of acute HBV infections and <1%/year of chronic HBV infection. Although spontaneous recovery results in lifelong protective immunity, trace amounts of HBV DNA appear sporadically in the circulation.² These trace amounts of HBV can be infectious and stimulate HBV-specific antibody and T-cell responses, which in turn control viremia. Thus, natural immunity is considered protective rather than sterilizing. This is because the transcriptional template of the virus, the covalently closed circular DNA (cccDNA), persists in the form of a minichromosome in host cells.³ Immunosuppression, e.g., as part of cancer chemotherapy or

Abbreviations: cccDNA, covalently closed circular DNA; HBV, hepatitis B virus; HCV, hepatitis C virus; IFN-α, interferon-alpha; ISG, IFN-stimulated gene; PBMC, peripheral blood mononuclear cells; SOCS3, suppression of cytokine signaling 3; WHV, woodchuck hepatitis virus.

From the ¹Immunology Section, Liver Diseases Branch, NIDDK, National Institutes of Health, DHHS, Bethesda, MD, USA; ²Emerging Infectious Diseases, Duke-NUS Graduate Medical School and ³Singapore Institute for Clinical Sciences, A*STAR, Singapore.

Received December 17, 2013; accepted July 12, 2014.

Supported in part by the Intramural Research Program of the NIH, NIDDK (to B.R.) and by a Singapore Translational Research (STaR) Investigator Award (NMRC/STaR/013/2012) (to A.B.).
organ transplantation, carries the risk of HBV reactivation.\(^1\) An ideal antiviral therapy should therefore not just decrease HBV replication but also eliminate or at least control cccDNA. Antiviral therapy may need to synergize with and ideally boost adaptive immune responses to achieve this.

**Interferon (IFN)-α-Based Therapy.** The rationale for using IFN-α to treat chronic HBV infection is identical to its use in chronic HCV infection: IFN-α exerts direct antiviral effects and induces complex immune alterations that ideally result in the clearance of the respective viruses.

In a small percentage of patients with chronic HBV infection IFN-α-based therapy results in HBeAg and HBsAg loss, seroconversion to anti-HBe and anti-HBs status, reduction of viral replication, and alanine aminotransferase (ALT) normalization.\(^4\) High doses of IFN-α have been shown to induce the degradation of HBV cccDNA in cell culture models by up-regulating the expression of the deaminase APOBEC3A and to

---

**Table 1. Comparison of Clinical, Virological, and Immunological Features of HBV and HCV Infection**

|                      | HBV                                      | HCV                                      |
|----------------------|------------------------------------------|------------------------------------------|
| Chronic infections   | 350 million people infected              | 170 million people infected              |
| Cause of chronic infection | Mostly vertical/perinatal transmission: mother-to-neonate transmission most common worldwide, followed by childhood infection | Mostly horizontal transmission: injection drug use, parenteral, sexual, nosocomial |
| Virology             | Virus 42 nm; enveloped nucleocapsid; partially double-stranded DNA genome | Virus 50 nm; enveloped nucleocapsid; positive stranded RNA genome |
|                      | Family Hepadnaviridae                    | Flaviviridae; Hepacivirus genus          |
|                      | Genotypes 8 genotypes                    | 6 major genotypes; more than 50 subtypes; quasi species in each infected patient |
| Mutation rate        | Low                                      | High                                     |
| Virus half-life       | 2-3 days                                 | 3 hours                                  |
| Virus production      | \(10^{10}-10^{12}\) virions/day          | \(10^{12}\) virions/day                  |
| Natural immunity     | Minimal IFN and ISG response             | Strong IFN and ISG response              |
| Protective response   | T cells, neutralizing antibodies         | T cells; transient strain-specific neutralizing antibodies? |
|                      | T cells, neutralizing antibodies         | Yes                                      |
| Virus clearance       | No; cccDNA (transcriptional template) may persist; disease reactivation possible | |
| Therapy of chronic infection | HBV replication | HCV replication |
|                      | HBV transcription (cccDNA)               |                                          |
| IFN-α based therapy  | - Cure (seroconversion) possible but rare; | Cure (SVR) possible                      |
|                      | - Indicates epigenetic changes in cccDNA; |                                          |
|                      | - Slow decrease in viral titer;         |                                          |
|                      | - ISG and NK cell activation             | - Fast decrease in viremia;              |
|                      | - Suppression of HBV-spec. T cells       | - ISG and NK cell activation in inverse correlation topretreatment levels (genetically determined); |
|                     |                                          | - Suppression of HCV-spec. T cells       |
| IFN-free antiviral therapy | - Cure (seroconversion) very unlikely;  | - High incidence of cure (SVR)           |
|                      | - Fast reduction in viremia              | - Decreased ISG expression               |
|                      | - Partial reversal of T-cell exhaustion  | - Fast reduction in viremia              |
|                      |                                          | - Partial reversal of T-cell exhaustion  |

Abbreviations: IFN, interferon; ISG, interferon-stimulated gene; NK cell, natural killer cell; SVR, sustained virological response.
Deaminate cccDNA, presumably when it is transiently rendered single-stranded by RNA polymerase II before transcription initiation. Cytidine deamination results in apurinic/apyrimidinic site formation and in degradation of cccDNA degradation by endonucleases. IFN-α also induces epigenetic changes in cccDNA-bound histones, which results in inhibition of HBV replication and decreases the transcription of pregeneic RNA and subgenomic RNA from cccDNA. Finally, IFN-α accelerates decay of nucleocapsids that contain pregenomic HBV RNA. The direct antiviral effect of IFN-α is sufficient to induce a reduction in viral load and HBV antigen levels as shown in HBV-infected humanized uPA/SCID mice that lack immune cells.

Successful antiviral treatment also appears to synergize with the natural trend to viral control in some patient populations, such as HBeAg+ patients with increased aminotransferase levels. These patients are not only more likely to establish partial immune control of HBV replication with seroconversion to HBeAg-negative/anti-HBeAg-positive status and a decrease in disease activity, but are also more likely to respond to antiviral therapy.

Unfortunately, both the induction of endogenous IFN-α during the natural course of HBV infection and the antiviral function of exogenously administered IFN-α are not fully effective in most patients. Patients with acute HBV infection or HBV reactivation do not have much evidence of IFN-α production, and IFN-stimulated genes (ISGs) are neither significantly induced in the livers of chimpanzees with acute HBV infection nor in the livers of woodchucks chronically infected with woodchuck hepatitis virus (WHV), which is closely related to HBV. The reasons for HBV’s ability to avoid a robust IFN-α-mediated innate response are controversial and have been reviewed in detail elsewhere. In addition to hiding from intracellular innate immune mechanism of pathogen detection, HBV may prevent Jak STAT signaling. To explain the overall low antiviral effect of IFN-α on HBV-infected hepatocytes, a recent report has suggested that its antiviral activity is mediated by exosomes that are secreted by noninfected nonparenchymal cells.

The limited antiviral effects of IFN-α in HBV infection are reflected by the relatively small percentage of patients with chronic HBV infection who respond to IFN-α-based therapy with HBeAg and HBsAg loss, seroconversion to anti-HBe and anti-HBs status, reduction of viral replication, and ALT normalization. A decrease in HBV viremia is observed about 3-4 weeks after the start of IFN-α-based therapy and takes several months to reach its maximum, whereas a sharp decrease in HCV viremia occurs within the first 48 hours of IFN-α-based therapy.

This delayed kinetic may reflect a progressive recovery of immune-mediated endogenous antiviral mechanisms, which, however, have scarcely been analyzed. A recent study characterized innate and adaptive immune responses of HBeAg-negative HBV-infected patients during 48 weeks of pegylated (Peg)IFN-α therapy. The decrease in HBV viremia coincided with an increase in the frequency of circulating CD56bright natural killer (NK) cells, increased expression of the activator receptor Nkp46, and the cytotoxic receptor TRAIL by NK cells and recovery of their IFN-γ production. The improved function of CD56bright NK cells paralleled an increase in IL-15 levels, which may have stimulated the NK cells. These observations were subsequently extended to HBeAg-positive patients. Interrogation of the transcriptome of peripheral blood mononuclear cells (PBMC) showed ISG induction within 6 hours after the start of therapy. This study also confirmed the ability of IFN-α treatment to boost IL-15 (in addition to IL-6 and CXCL-10) levels and to trigger NK cell proliferation. However, the robust activation of innate immune parameters was not associated with a decrease in HBV titer within the first 2 weeks of therapy, suggesting that the modulation of innate immune responses was a direct effect of the administered IFN-α and not secondary to its antiviral effect.

In contrast to innate immune responses, HBV-specific T-cell responses did not recover during IFN-based therapy. This is unexpected because IFN-α is known to increase T-cell survival, expression of antigen-processing enzymes, cross-presentation of T-cell antigens, and production of interleukin (IL)-12, a cytokine that has been shown to rescue the function of exhausted HBV-specific T cells in vitro. While the frequency of activated T cells increases within the first 2-3 days of IFN-α-based therapy, a numeric reduction in CD8 T cells, in particular late effector CD8 T cells, is observed during long-term treatment. Moreover, the HBV-specific CD8 T-cell subset maintains expression of inhibitory cell surface markers such as PD-1, Lag-3, and CTLA-4, and thus remains nonfunctional throughout therapy. Similar negative effects of IFN-α on virus-specific adaptive immunity have recently been emphasized in two studies of mice that were chronically infected with lymphocytic choriomeningitis virus. In these studies, T-cell responses were restored by inhibiting the effects of virus-induced IFN-α rather than by treating the infection with IFN-α. Although this scenario is not fully applicable to HBV-infected patients, where IFN-α signaling is suppressed, the strong and continued activation of ISGs during IFN-α-based
therapy may negatively impact the function of HBV-specific T cells. Accordingly, flares in liver disease activity are often observed after cessation of IFN-based therapy. Seroconversion to anti-HBe may follow a flare, and is specifically associated with an increase in IL-12, IFN-γ, and IL-2 serum levels. While a recovery of CD8 T-cell function is not observed during IFN-based therapy, cytotoxic CD8 T-cell lines can be more readily expanded from the blood of patients who have responded to IFN-based therapy with anti-HBe or with anti-HBe/anti-HBs seroconversion than from nonresponders.

Thus, IFN-α-based therapy stimulates predominantly innate immune responses. A note of caution is warranted because all published data are based on interrogation of immune responses in the blood. Although reduced expression of ISGs in the liver of chronic HBV patients mirrors that in PBMCs, the intrahepatic microenvironment poses additional limitations to the effector arm of antiviral immunity. For example, intrahepatic levels of suppression of cytokine signaling 3 (SOCS3), a negative regulator of cytokine signaling, are increased in patients with chronic HBV infection and in woodchucks with chronic WHV infection. SOCS3 has not only been associated with HBV’s or WHV’s ability to evade innate immunity but it is a predictor of poor IFN-α responses in HCV-infected patients and as such may also impact the therapeutic efficacy of IFN-α in patients with chronic HBV infection. Because the intrahepatic environment in chronic HBV infection is also rich in IL-10, transforming growth factor beta (TGF-β), and arginase, factors that impair both T and NK cell function, it may not be surprising that the activation of innate immune cells within the first hours of IFN-α treatment is not accompanied by a reduction in HBV titer. A decrease in intrahepatic inflammation, as observed in chronic HBV patients who are treated with NUCs, may be required to restore immune responses in the liver.

**Therapy With Nucleos(t)ide Analogs (NUC).** HBV-DNA titers decline rapidly in blood and liver during treatment with NUCs, and inflammatory liver disease improves. The potent antiviral effect of NUCs is based on an inhibition of the reverse transcriptase function of the HBV DNA polymerase, the enzyme responsible for HBV replication. The rapid reduction of viral replication should theoretically blunt any potential immunomodulatory effect of HBV and restore IFN-α signaling in infected hepatocytes. This hypothesis is supported by the recent description of a progressive expression of ISGs in PBMCs of HBeAg+ HBV-infected patients as early as day 8 of treatment with tenofovir along with a 100-fold decrease in HBV titer.

The impact of NUC treatment on innate immune cells is controversial. While a recovery of the function of myeloid dendritic cells has been observed in adefovir-treated patients, the effect of NUCs on NK cells is less clear. An improvement of NK cell IFN-γ production has been described in a study of entecavir-treated patients, but other studies of adefovir and lamivudine-treated patients did not confirm these results and instead showed decreased expression of the NK cell effector molecule TRAIL. Since TRAIL-mediated hepatocyte lysis is thought to contribute to liver injury and inflammation in chronic HBV infection, the latter finding would be consistent with the decrease in liver inflammation that is characteristic for treatment with NUCs.

The reported effects of NUC treatment on adaptive immune cells are more consistent, because an increased frequency and function of HBV-specific CD4 and CD8 T cells is reported in multiple studies. Telbivudine and lamivudine both reduce the expression of the inhibitory molecule PD-1 on total T cells and their HBV-specific subset, and telbivudine has also been associated with improved production of IL-21 and recovery of follicular helper T cells, which provide functional help to both T and B cells. However, this recovery of T-cell function remains incomplete and quantitatively not comparable to adaptive immune responses of patients who spontaneously control HBV infection. It is mainly detectable with assays that are based on in vitro expansion of T cells and not readily observed with ex vivo assays. Furthermore, restoration of HBV-specific T-cell responses can be transient, which may contribute to the frequent failure of HBV control when treatment is discontinued. Likewise, NUC-mediated HBV suppression is not sufficient to restore responsiveness to HBsAg vaccination and lamivudine/IL-12 combination therapy is equally ineffective in boosting HBV-specific T-cell responses.

While a consensus exists on the ability of NUC therapy to partially recover HBV-specific T-cell function, the underlying mechanisms are controversial. It has been suggested that a substantial decline of HBV antigen levels in the blood is required for recovery of T-cell function, because high HBV antigen levels are regarded as the cause of HBV-specific T-cell deletion and exhaustion in natural infection. Unfortunately, with the exception of very few patients who clear HBsAg during treatment, NUCs have little impact on HBV antigen levels, particularly in the first year of therapy when HBV-specific T-cell recovery is more
pronounced. As an alternative hypothesis it has been
proposed that decreased HBV replication by limiting
HSP60 release from infected hepatocytes, results in a
secondary decrease in the frequency of CD4 T cells
with regulatory/suppressor capacity (Tregs).56 According
to that hypothesis, NUC-mediated inhibition of HBV
replication and reduction in Treg frequency would
enhance the HBV-specific T-cell response.57 However,
even though a reduced frequency of circulating Treg
cells was observed in entecavir-, adefovir-, and
tenofovir-treated patients,56,58,59 it is not clear whether
this is the result of reduced HBV replication or reduced
liver inflammation.

In this context, it is surprising that a direct immu-
nomodulatory effect of NUCs has not been contemplat-
ed in HBV infection. Tenofovir and adefovir have
been shown to increase the production of TNF-α, IL-
6, IL-10, CCL5 (Rantes), and CCR5 (MIP-1α) in
human monocytes.60 Tenofovir has also been shown to
modulate Toll-like receptor (TLR)-mediated responses
and to reduce the threshold of T-cell activation.61 A
better evaluation of these direct immune effects is
attractive because further attempts to boost HBV-
specific immune responses will be performed in
patients in whom HBV replication is suppressed by
some of the potent NUCs. Along this line, it has been
shown that entecavir enhances the effects of therapeutic
vaccination in the woodchuck model of chronic hepatitis.62

**IFN-α/NUC Combination Therapy.** The limited
efficacy of IFN-α or NUC monotherapy in achieving
HBsAg seroconversion and/or sustained HBV control
was the rationale for studies that combine the two
classes of drugs. Because NUCs potently inhibit HBV
replication and partially restore HBV-specific T-cell
responses, and because IFN-α targets HBV cccDNA
and stimulates NK cell responses, the combination of
IFN-α and NUCs may generate a better antiviral
response and immune recovery in patients with
chronic HBV infection. Combination NUC/PegIFN-α
therapy does indeed have a slightly better on-treatment
antiviral effect in HBeAg+ and in HBeAg- patients
than IFN-α or NUC monotherapy, but the rate of sus-
tained off-treatment responses is not higher than with
PegIFN-α monotherapy.63-68 A longitudinal study of
lamivudine and PegIFN-α-treated children with
infancy-acquired HBV infection, a patient group that
is considered immunotolerant, demonstrated a recov-
ery of HBV-specific T-cell responses in those who
responded with HBsAg loss.69 The magnitude of the
recovered T-cell response was, however, weak and a
comparison with children treated with lamivudine
monotherapy was not performed. Based on recent
data, an extended period of viral suppression prior to
NUC/PegIFN-α combination therapy may increase the
HBs seroconversion rate, as evidenced by HBsAg loss
in 60% of patients who were treated with PegIFN and
entecavir after more than 3 years of complete viral
suppression by entecavir monotherapy.70

**Immunological Aspects of HCV Antiviral
Therapy**

In contrast to HBV, HCV can be completely cleared
by an individual’s immune response. Key mediators of
spontaneous HCV clearance are virus-specific T cells
(reviewed in71), which remain readily detectable in the
circulation for decades after clearance.72 Studies in
chimpanzees were important to demonstrate that these
T cells protect upon reinfection because depletion of
either CD4 or CD8 T cells after recovery from a pri-
mary challenge abrogates protective immunity upon
HCV rechallenge.73,74 Based on the fact that acute
HCV infection can be cleared spontaneously, effective
antiviral therapy of chronic infection should be able to
completely eliminate HCV without the risk of relapse.
This is supported by the experience that a sustained
virological response (SVR) after IFN-based therapy is
durable in more than 97% of patients.75

Over the past three decades, treatment regimens
have evolved from IFN-α to PegIFN-α/ribavirin com-
bination therapy,76 to inclusion of the first protease
inhibitors and, most recently, to potent interferon-free
combinations of two and three direct-acting antivi-
rals.77,78 In addition, the use of IFN-α has stimulated
virological and immunological studies on host
responses to endogenous and therapeutic IFN-α. This
line of research has, for example, led to the discovery
of genetic determinants of IFN-responsiveness79-82 and
to the identification and characterization of key mole-
cules in antiviral defense, such as the signaling mole-
cule MAVS83 and a broad spectrum of antiviral IFN-
stimulated genes.84

**IFN-α-Based Therapy.** IFN-α was used to treat
patients with chronic HCV infection, then known as
non-A non-B hepatitis, years prior to the identification
of the virus itself.85 Treatment outcomes improved sig-
ificantly after the nucleoside analog ribavirin was
added to prevent relapse86 and again, after IFN-α’s
pharmacokinetics was optimized by pegylation
(PegIFN-α).87 Treatment responders typically exhibit a
1-2 log10 decline in viremia within 1-2 days of treat-
ment initiation, a response that is, as discussed, much
faster than that observed in HBV-infected patients.
This first-phase response is thought to be due to inhibition of HCV replication and is followed by a slower second-phase response. The overall response to therapy is determined by viral factors such as viral titer and genotype and by host factors, which include age, race, gender, cirrhosis, comorbidities, and the baseline activation level of the endogenous IFN-α response.

IFN-α-based therapy of acute HCV infection is highly successful, with >90% of patients responding. This may be due to the fact that a type II IFN signature prevails at the time of maximal intrahepatic T-cell responses in acute infection (due to IFN-γ production by HCV-specific T cells) and that type I IFN-induced negative feedback and resistance mechanisms are not yet fully induced. In contrast, IFN-α-based therapy has much lower response rates in chronic HCV infection. High pretreatment levels of type I and type III interferon induced genes and the presence of the unfavorable rs12979860-T allele in the IFNL3 gene locus are associated with treatment nonresponse. Presence of the ΔG allele of the ss469415590 variant (IFNL4-ΔG) adds negative predictive value in African Americans. While the molecular mechanisms that underlie these associations require further investigation, it has become clear that high baseline ISG levels limit further induction of these genes during IFN-α-based therapy. Induction of negative feedback mechanisms, such as SOCS likely contributes to this refractoriness.

A patient’s responsiveness to IFN-α-based therapy can also be assessed by the activation of innate immune cells. Similar to what is observed during IFN-α-based therapy of chronic hepatitis B, NK cells are strongly activated within hours of IFN-α injection with increased cytotoxicity and decreased IFN-γ production. This response pattern is due to IFN-α-mediated induction of STAT1 in NK cells, which displaces STAT4 at the IFN-α/β receptor. Continued IFN-α stimulation then results in preferential STAT1 over STAT4 phosphorylation, with an increase in pSTAT1-dependent NK cell cytotoxicity and a decrease in pSTAT4-dependent IFN-γ production. Accordingly, NK cells from patients with a rapid first phase HCV RNA decline exhibit maximal responsiveness to type I IFN as evidenced by a high induction of pSTAT1 in NK cells compared to patients with slow HCV RNA decline. This is consistent with greater NK cell cytotoxicity in treatment responders than nonresponders.

The negative correlation between pretreatment and on-treatment activation of IFN-α-responsive immune cells such as NK cells recapitulates what has been reported for intracellular ISGs in hepatocytes. For example, the expression levels of the activating NK cell receptors NKP30, NKP46, and DNAM-1 correlate inversely with the increase in these parameters during IFN-α-based treatment and the subsequent virological treatment response. Similar to chronic activation of the innate immune response, chronic activation of the adaptive immune response also predicts treatment failure. This is evidenced by increased pretreatment expression of the programmed death 1 (PD-1) molecule on lymphocytes of treatment nonresponders. Expression of PD-1 reflects T-cell activation by way of the T-cell receptor, and PD-1 blockade by itself, is not sufficient to induce HCV clearance in the chimpanzee model. Longitudinal analysis of HCV-specific T-cell reactivity during IFN-based therapy has shown some differences between those with a fast and slow early response. Overall, however, IFN-α-based therapy suppresses rather than stimulates HCV-specific T cells. As in chronic HBV infection, the frequency of HCV-specific T cells and their capacity to produce IFN-γ decreases in HCV-infected patients who undergo IFN-α-based therapy. An exception is treatment during the acute phase of HCV infection. Although the bulk HCV-specific T-cell response as measured by IFN-γ production in response to overlapping HCV peptides also decreases when patients with acute HCV infection are treated, a very small population of HCV-specific memory T cells can be rescued.

Ribavirin. The guanosine analogue ribavirin is a component not only of interferon-based therapies for HCV but also of new therapies with direct-acting antivirals (DAAs). While ribavirin itself only has a modest effect on HCV RNA levels and does not induce viral clearance, it is associated with a faster second-phase virological response when administered together with PegIFN-α, and it decreases on-treatment virological breakthrough and posttreatment virological relapse and/or DAAs. Several direct effects on viral replication have been proposed as ribavirin’s mechanism of action. These include inhibition of the HCV NS5B-encoded RNA polymerase, depletion of guanosine triphosphates by interference with a host enzyme, and promotion of viral error catastrophe (reviewed in ). While each of these mechanisms is supported by in vitro data, several in vivo observations argue against a primarily antiviral mode of action. For example, ribavirin monotherapy results only in a modest, less than a 1 log₁₀ decline in viral levels, does not increase the rate of nucleotide substitutions, and does not improve the first-phase virological decline in combination therapy with PegIFN-α. An immunomodulatory
effect has been proposed because ribavirin induces a set of ISGs that differs from those induced by IFN-α and may improve the ability of the HCV-infected liver to respond to IFN-α-based therapy. Consistent with this proposed synergistic action, ribavirin accelerates the second-phase virological response in patients with a suboptimal, but not absent, interferon response. In addition, ribavirin counteracts IFN-α’s negative effect on NK cell IFN-γ production to some extent and improved IFN-γ production by NK cells correlates with the second-phase virological response. Whether it also contributes to better immunosurveillance and prevention of virological relapse is an interesting question for further studies. Finally, ribavirin was shown to enhance T-cell function and to inhibit production of the immunosuppressive cytokine IL-10 in vitro but this has not been confirmed with T cells from treated patients.

DAAs. The development of interferon-free regimens that combine two or three DAAs and achieve high response rates for genotypes 1, 2, and 3 infections is exciting not only from a clinical, but also from an immunological perspective. A key question is whether effective inhibition of HCV replication restores defective innate and adaptive immune responses. Inhibition of HCV replication by interferon-free DAA regimens may decrease the virus-induced ISG signature and restore IFN-responsiveness. It would also be of interest to investigate whether these regimens recover NK cell IFN-γ production, which is suppressed in chronic HCV infection. Finally, it is important to investigate whether exhausted and dysfunctional T-cell responses recover. A recent study demonstrates that both the frequency of HCV-specific CD8 T cells in the blood and their proliferative in vitro response increases in DAA responders but not in nonresponders. Of note, DAA-mediated viral clearance preferentially increased the frequency of T cells that targeted conserved HCV epitopes—most of these T cells were thought to be exhausted due to chronic antigenic stimulation. While it is not possible to distinguish between the outgrowth of a small number of functional T cells and reversion of T-cell exhaustion, and while it is not yet clear whether increased proliferation is associated with increased effector function, it is important that a functional T-cell response may contribute to prevention of viral relapse and establishment of long-term immunity against reinfection. Future studies may clarify the extent and mechanisms of improved T-cell function. A reversion of T-cell exhaustion may also be relevant for other diseases, such as HIV infection and cancer, where T-cell exhaustion has been described.

Future Directions

For chronic hepatitis B, the current treatment regimens rarely result in complete eradication of the virus and its cccDNA. New regimens are needed that complement antiviral therapy with strategies to induce better immune control. This may be achieved by enhancing immune responses directly (TLR-agonists, vaccine therapy, adoptive T-cell therapy) or indirectly (through inhibition of HBsAg production). For chronic HCV infection, the prospect is different because antiviral therapies can completely eradicate the virus. IFN-α-free regimens that are effective against all HCV genotypes and that can be administered orally with minimal side effects appear within reach. However, even with a reduction in treatment duration and costs, these regimens will likely not be affordable in countries where the prevalence of HCV and the incidence of new infections are highest. The development of a prophylactic vaccine that induces protective immunity is therefore still worth pursuing.

References

1. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009;49: S156-165.
2. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-1108.
3. Leverero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-592.
4. Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 2011;8:275-284.
5. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-1228.
6. Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, et al. Alpha-interferon suppresses hepatadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013;9: e1003615.
7. Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, et al. IFN-alpha inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest 2012;122:529-537.
8. Pasquerto V, Wieland SF, Uprichard SL, Tripodi M, Chisari FV. Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures. J Virol 2002;76:5646-5653.
9. Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, et al. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol 2010;84:9332-9340.
10. Allweiss L, Volz T, Lutgehetmann M, Giersch K, Bornscheuer T, Lohse AW, et al. Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. J Hepatol 2014;60:500-507.
11. Dunn C, Peppa D, Khania P, Nebbia G, Jones M, Brendish N, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009;137:1289-1300.
31. Patzwahl R, Meier V, Ramadori G, Mihm S. Enhanced expression of
30. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng
29. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M,
26. Spadaro F, Lapenta C, Donati S, Abalsamo L, Barnaba V, Belardelli F,
25. Shin EC, Seife U, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al.
24. Marrack P, Kaye D, Mitchell T, Type I interferons keep activated T
23. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH.
19. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al.
18. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongpavat S, Cooksey G, et al.
17. Li J, Liu K, Liu Y, Xu Y, Zhang F, Yang H, et al. Exosomes mediate
16. Christen V, Duong F, Bernsmeier C, Sun D, Nassal M, Heim MH.
15. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis
12. Wieland S, Thimme R, Purcell RH, Chisari FV. Genomic analysis of
11. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al.
48. TrehanPatil N, Kortili S, Hisaar SS, Shrivastava S, Khanam A, Sukriti S, et al. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol 2011:31:509-520.
47. Chen Y, Li X, Ye B, Yang X, Wu W, Chen B, et al. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Res 2011:91:23-31.
46. Evans A, Riva A, Cooksey H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology 2008;48:759-769.
45. Cooksey H, Chokshi S, Maayan Y, Wiedemeyer H, Andreone P, Gelison R, et al. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob Agents Chemother 2008:52:312-320.
44. Boni C, Penna A, Ogg GS, Bertolatti A, Pilli M, Cavallo C, et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001:33:963-971.
43. Boni C, Penna A, Bertoletti A, Lamonaca V, Alferri A, et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003:39:653-660.
42. Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Peginterferon-alfa-2a alone, lamivudine alone, and the two in combination. HEPATOLOGY 2006;43:1239-1246.
41. Tjwa ET, van Oord GW, Hegenmans JP, Janssen HL, Wolteman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis C. J Hepatol 2011:55:209-218.
40. van der Molen RG, Sprengers D, Biesta PJ, Kusters JG, Janssen HL, Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBV. HEPATOLOGY 2010;52:1611-1620.
39. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-responsiveness to interferon therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006:55:529-535.
38. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009:137:1593-1608.
37. Das A, Maini MK. Innate and adaptive immune responses in hepatitis B virus infection. Dig Dis 2010:28:126-132.
36. Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, et al. TGF-beta1 down-regulation of NKG2D/DAPI10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog 2012:8:e1002594.
35. Peppa D, Micco L, Javid A, Kennedy PT, Schurich A, Dunn C, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog 2010:6:e1001227.
34. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006:55:529-535.
33. Reherrmann B, Lau D, Hoofnagle JH, Chisari FV. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest 1996:97:1655-1665.
32. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006:55:529-535.
long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012;143:963-973.

52. Tan AT, Koh S, Goh W, Zhe HY, Gehring AJ, Lim SG, et al. A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol 2010;52:330-339.

53. Vandepapeliere P, Lau GK, Leroux-Roels G, Homsans Y, Gane E, Tawande T, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007;25:8585-8597.

54. Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005;42:1028-1036.

55. Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 2013;11:1004-1010.

56. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS. Decreased inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr 2011;57:265-275.

57. Franzese O, Kennedy PT, Gehring AJ, Gatto J, Williams R, Maini MK, et al. Modulation of the CD8+ T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005;79:3322-3328.

58. Zhang JY, Song CH, Shi F, Zhang Z, Fu JL, Wang FS. Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment. PLoS One 2010;5:e13869.

59. Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL. Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virolology 2007;361:141-148.

60. Zidek Z, Frankova D, Holy A. Activation by 9-(R)-[2-(phosphonomethoxy)propyl]adenine of chemokine (RANTES), macrophage inflammatory protein [alpha] and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-beta) production. Antimicrob Agents Chemother 2001;45:3381-3386.

61. Melchjorsen J, Risor MW, Sogard OS, O'Loughlin KL, Chow S, Paladzn SR, et al. Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells. J Acquir Immune Defic Syndr 2011;57:265-275.

62. Cosinska AD, Zhang E, Jorkden L, Liu J, Seiz PL, Zhang X, et al. Peginterferon alfa-2b plus adefovir induce strong immune response in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol 2011;26:1527-1535.

63. Carey I, D'Antiga L, Bansal S, Longhi MS, Ma Y, Mesa IR, et al. Immune and viral profile from tolerance to hepatitis B surface antigen clearance: a longitudinal study of vertically hepatitis B virus-infected children on combined therapy. J Virol 2011;85:2416-2428.

64. Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleos(t)ide analogs. J Clin Virol 2013;58:713-717.

65. Park SH, Rehermann B. Immune responses to HCV and other hepati-

66. Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, et al. Decreased immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6:578-582.

67. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302:659-662.

68. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghayeb J, Reimann KA, et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003;197:1645-1655.

69. Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009;49:665-675.

70. Hein M. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol 2013;13:535-542.

71. Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013;368:1907-1917.

72. Liang TJ, Ghany MG. Therapy of hepatitis C—in the future. N Engl J Med 2014;370:2043-2047.

73. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.

74. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-1104.

75. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.

76. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013;45:164-171.

77. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003;300:1145-1148.

78. Schoogins JW, Wilson SJ, Panis M, Murphy MI, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011;472:481-485.

79. Hoofnagle JH, Menacho LD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.

80. Reichard O, Norkrans G, Fryden A, Bracconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon-alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-87.

81. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.

82. Juedes JF, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452-1457.

83. Dill MT, Malowska Z, Duong FH, Merleker F, Filipowicz M, Baumert TF, et al. Interferon-gamma-stimulated genes, but not
USP18, are expressed in livers of patients with acute hepatitis C. Gastroenterology 2012;143:777-786 e771-776.

90. Sarasin-Filipowicz M, Wang X, Van M, Duong FH, Poli V, Hilton DJ, et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Mol Cell Biol 2009;29:4841-4851.

91. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141:1231-1239.

92. Miyagi T, Gil MR, Wang X, Louten J, Chu WM, Biron CA. High basal STAT4 balances by STAT1 induction to control type 1 interferon effects in natural killer cells. J Exp Med 2008;180:2383-2396.

93. Edlich B, Ahlenstiel G, Aspiroz AZ, Stoltzfus J, Noureddin M, Serti E, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012;55:39-48.

94. De Maria A, Fogli M, Maaza S, Baso M, Picciotto A, Costa P, et al. Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients. Eur J Immunol 2007;37:445-455.

95. Golden-Mason L, Klarquist J, Wahed AS, Rosen HR. Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: race-dependent differences. J Immunol 2008;180:3637-3641.

96. Rutkemberwa A, Ray SC, Axelorborski J, Levine J, Liu L, Dowd KA, et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral presence and require preservation of cognate antigen during chronic infection. J Immunol 2008;181:8215-8225.

97. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A 2013;110:15001-15006.

98. Tang KH, Herrmann E, Cooksey H, Taitman N, Choleski S, Williams R, et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Hepatol 2005;43:776-782.

99. Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky J, et al. Role of the HCV-specific T cell response in relation to viral kinetics and treatment outcome in PEG-Interferon-alpha-2a and Ribavirin therapy (DITTO-HCV project) for chronic hepatitis C. Gastroenterology 2007;133:1132-1143.

100. Rahman E, Heller T, Sebato Y, Mizukoshi E, Nascimbeni M, Alter H, et al. Effects of antiviral therapy on the cellular immune response in acute hepatitis C. Hepatology 2004;40:87-97.

101. Lauer GM, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, et al. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 2005;79:12979-12988.

102. Badr G, Bedard N, Abdel-Hakeem MS, Trautmann I, Willems B, Villeneuve JP, et al. Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 2008;82:10017-10031.

103. Pawlotsky JM, Dahari H, Neumann AU, Hezode C, Germanidis G, Lonjon I, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703-714.

104. Rotman Y, Noureddin M, Feld JJ, Guerd J, Winthaus M, Han H, et al. Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut 2014;63:161-169.

105. Fried MW, Shiffman ML, Reddy KR, Smith C, Marininos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.

106. Hezode C, Forestier N, Duheiko G, Ferenci P, Poi S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-1850.

107. Feld JJ. Is there a role for ribavirin in the era of hepatitis C virus direct-acting antivirals? Gastroenterology 2012;142:1556-1559.

108. Dietz J, Schellhorn SE, Fitting D, Mihm U, Susser S, Welker MW, et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J Virol 2013;87:6172-6181.

109. Herrmann E, Lee JH, Marininos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C virus kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351-1358.

110. Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, Casola A, et al. Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 2003;77:5933-5947.

111. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2011;53:32-41.

112. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007;46:1548-1563.

113. Feld JJ, Lutchnau GA, Heller T, Hara K, Pfeiffer JK, Leff RD, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010;139:154-162 e154.

114. Werner JM, Serti E, Chepa-Loreta X, Stoltzfus JD, Ahlenstiel G, Feld JJ, et al. Ribavirin resets the STAT4 dependent IFN-γ responsiveness of natural killer cells in hepatitis C. Hepatology 2013;58:1106A.

115. Barnes E, Harcourt G, Brown D, Lucas M, Phillips R, Dusheiko G, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatology 2002;36:743-754.

116. Ahlenstiel G, Titerence RH, Koh C, Edlich B, Feld JJ, Rotman Y, et al. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner. Gastroenterology 2010;138:325-335.

117. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009;137:1151-1160, 1160 e1151-1157.

118. Martin M, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 2014 [Epub ahead of print].